Prolight Diagnostics, together with our subsidiary Psyros Diagnostics Ltd., develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.

The aim of POC systems is to achieve the same performance as hospital laboratories, so that doctors and healthcare professionals can make a correct diagnosis quickly and safely. This allows more rapid treatment already when the patient presents for the first time at, for example, an emergency department, a healthcare centre, an ambulance, or a care home.

The novel single molecule counting (digital) immunoassay technology was incorporated into Prolight in early 2022, through the acquisition of the UK company Psyros Diagnostics Ltd. Psyros has developed a new, cutting-edge POC technology for digital immunoassay. Psyros has a highly competent team with lengthy and diverse experience in IVD (in-vitro diagnostic) development, specifically in POC tests and POC systems. The team has unique skills and experience that enhance the existing expertise in Prolight.

Prolight has recently demonstrated that its digital high-sensitive PsyrosTM immunoassay can measure protein concentrations down to single-digit nanograms per litre (ng/L) with laboratory-grade reproducibility. These low concentrations are required for high-sensitivity troponin assays, in order to rule out myocardial infarction.1 We obtained these proof-of-performance results in November 2022 initially by measuring thyroid stimulating hormone (TSH) levels in human plasma samples and subsequently in June 2023 by measuring troponin in serum samples.

The POC system MicroFlex was developed in partnership with The Technology Partnership (TTP). The platform combines the well-proven ELISA technology into a microformat with the Flex Membrane-technology, developed by TTP. The combination of these two technologies, MicroFlex, has the potential to achieve equivalent test performance as hospital laboratories, in a format which make it suitable for distributed diagnostic testing.

In November 2022 Prolight signed a commercialisation agreement for its proprietary point-of-care (POC) platform MicroFlex with The Technology Partnership plc (TTP). Under the agreement, TTP will pursue further development and ongoing external initiatives and discussions with the aim of securing an industrial partner for MicroFlex. Prolight Diagnostics will benefit under the commercialisation agreement as future revenues are generated.

Prolight has a strong patent portfolio. For the digital immunoassay, Prolight’s subsidiary Psyros Diagnostics Ltd has five patent applications filed. For MicroFlex, the patent portfolio consists of four granted patents along with four patent applications.

  1. European Cardiology Society’s Guidelines on Fourth Universal Definition of Myocardial Infarction